المؤلفون: Jesper van Breeschoten, Alfons J.M. van den Eertwegh, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Damjan Manevski, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters, Liesbeth C. de Wreede

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Medical Oncology

المصدر: European Journal of Cancer, 182, pp. 132-143
European Journal of Cancer, 182, 132-143. ELSEVIER SCI LTD
European Journal of Cancer, 182, 132-143. Pergamon
van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Manevski, D, Suijkerbuijk, K P M, Wouters, M W J M & de Wreede, L C 2023, ' Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry ', European Journal of Cancer, vol. 182, pp. 132-143 . https://doi.org/10.1016/j.ejca.2023.01.006Test
European Journal of Cancer, 182, 132-143
European Journal of Cancer, 182, 132-143. Elsevier Ltd.

مصطلحات موضوعية: Cancer Research, Multistate model, PHASE-3, Population mortality, Response status, MULTICENTER, Relative survival, Advanced melanoma, OPEN-LABEL, COMPETING RISKS, VEMURAFENIB, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], All institutes and research themes of the Radboud University Medical Center, Oncology, SDG 3 - Good Health and Well-being, Older patients, SURVIVAL, METASTATIC MELANOMA

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afee38642ca1159b695777f346821b37Test
http://www.scopus.com/inward/record.url?scp=85147863592&partnerID=8YFLogxKTest

المؤلفون: Patricio Serra-Bellver, Judith M. Versluis, Honey K. Oberoi, Cong Zhou, Timothy D. Slattery, Yasir Khan, James R. Patrinely, Inês Pires da Silva, C. Martínez-Vila, Natalie Cook, Donna M. Graham, Matteo S. Carlino, Alexander M. Menzies, Ana M. Arance, Douglas B. Johnson, Georgina V. Long, Lisa Pickering, James M.G. Larkin, Christian U. Blank, Paul Lorigan

المصدر: European Journal of Cancer. 176:121-132

مصطلحات موضوعية: History, Cancer Research, Nivolumab, Polymers and Plastics, Oncology, Brain Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Business and International Management, Ipilimumab, Melanoma, Industrial and Manufacturing Engineering, Retrospective Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc088fa3fd7d252dd7cf0be202702801Test
https://doi.org/10.1016/j.ejca.2022.09.004Test

المؤلفون: Oliver John Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye Boers-Sonderen, Anna Maria Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

المصدر: European Journal of Cancer.

مصطلحات موضوعية: Cancer Research, Oncology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5d76ea38d5272210700d8b7c6e66bf27Test
https://doi.org/10.1016/j.ejca.2023.04.016Test

المؤلفون: Thomas Eigentler, Cindy Franklin, Anja Gesierich, Claus Garbe, Sebastian Haferkamp, James Larkin, Sophia Kreft, Paul Lorigan, Bastian Schilling, Sara Valpione, Selma Ugurel, Jochen Utikal, Dirk Schadendorf, Christian U. Blank

المصدر: European Journal of Cancer. 116:207-215

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Adverse effect, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Salvage Therapy, business.industry, Immunotherapy, Middle Aged, medicine.disease, Confidence interval, Nivolumab, Treatment Outcome, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f33bef3ecdaf233f4184cbdb0bbc1eTest
https://doi.org/10.1016/j.ejca.2019.05.015Test

المؤلفون: Piotr Rutkowski, Wilson H. Miller, Ivana Krajsová, Christian U. Blank, Paola Queirolo, Ana Arance, Paul Lorigan, Mario Mandalà, Geke A. P. Hospers, Bart Neyns, Jacob Schachter, Vanna Chiarion Sileni, James Larkin, Martina Makrutzki, Enrique Espinosa, Alexander Guminski, Margarita Donica, Axel Hauschild, Gabriela Liszkay, Marta Nyakas, Michele Del Vecchio, Paolo A. Ascierto, Claus Garbe, Helen Gogas, Michael P. Brown

المساهمون: Clinical sciences, Medical Oncology, Laboratory of Molecular and Medical Oncology, Laboratory of Molecullar and Cellular Therapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: European Journal of Cancer, 107, 175-185. ELSEVIER SCI LTD

مصطلحات موضوعية: 0301 basic medicine, Oncology, safety, Cancer Research, medicine.medical_specialty, Dacarbazine, Population, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, METASTATIC MELANOMA, BRAF(V600) mutation, Vemurafenib, education, Cobimetinib, Medicine(all), education.field_of_study, business.industry, Melanoma, medicine.disease, Clinical trial, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Prognostic scoring system, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4770200b8acfba16c98dc5dbd5caf591Test
https://doi.org/10.1016/j.ejca.2018.11.018Test

المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser

المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test

المؤلفون: Christian U. Blank, Jacob Schachter, Claus Garbe, Paola Queirolo, Geke A. P. Hospers, Vanna Chiarion Sileni, Helen Gogas, Michael P. Brown, Bart Neyns, Ana Arance, Martina Makrutzki, Enrique Espinosa, Michele Del Vecchio, Vladan Antic, James E. Larkin, Wilson H. Miller, Ivana Krajsová, Mario Mandalà, Susan Robson, Axel Hauschild, Paolo A. Ascierto

المساهمون: Blank, Christian U, Larkin, James, Arance, Ana M, Hauschild, Axel, Brown, Michael Paul, Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: European Journal of Cancer, 79, 176-184. ELSEVIER SCI LTD

مصطلحات موضوعية: Oncology, safety, Cancer Research, medicine.medical_specialty, Keratoacanthoma, PHASE-3, Population, Ipilimumab, Metastatic melanoma, TRAMETINIB, BRAF, 03 medical and health sciences, chemistry.chemical_compound, DOUBLE-BLIND, 0302 clinical medicine, Internal medicine, Medicine, BRAF(V600) mutation, 030212 general & internal medicine, Vemurafenib, education, Trametinib, Cobimetinib, education.field_of_study, business.industry, Melanoma, IPILIMUMAB, Dabrafenib, RANDOMIZED CONTROLLED-TRIAL, COBIMETINIB, medicine.disease, EFFICACY, Dermatology, DABRAFENIB, chemistry, BRAFV600 mutation, 030220 oncology & carcinogenesis, SURVIVAL, Safety, business, medicine.drug, metastatic melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1910f4406e05fe60a840c0b441e9987Test
https://doi.org/10.1016/j.ejca.2017.04.007Test

المؤلفون: Christian U. Blank, Michele Maio, Michael A. Postow, Benjamin Weide, Phillip Wong, Dirk Schadendorf, Anna Maria Di Giacomo, Florian Heubach, Jianda Yuan, Paolo A. Ascierto, Amir Khammari, Marnix H Geukes Foppen, Brigitte Dréno, Graham Pawelec, Claus Garbe, Emanuela Romano, Domenico Mallardo, Bastian Schilling, Jedd D. Wolchok, Kilian Wistuba-Hamprecht, Alexander Martens

المساهمون: Department of Dermatology [Tubingen, Germany], University Medical Center [Tubingen, Germany], Department of Internal Medicine II [Tübingen, Germany], University Medical Center [Tübingen, Germany], Immunité et cancer (U932), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), The Netherlands Cancer Institute [Amsterdam, The Netherlands], Memorial Sloane Kettering Cancer Center [New York], Weill Medical College of Cornell University [New York], Istituto Nazionale Tumori Fondazione Pascale [Naples, Italy], Department of Dermatology [Essen, Germany], University Hospital [Essen, Germany]-West German Cancer Center [Essen, Germany]-University Duisburg-Essen [Germany], German Cancer Consortium [Heidelberg] (DKTK), Division of Medical Oncology and Immunotherapy [Siena, Italy], University Hospital of Siena, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), School of Science and Technology [Nottingham, U.K.], Nottingham Trent University, Division of Cancer Studies [London, UK], King‘s College London, Parts of this study were funded by Bristol-Myers Squibb (Munich, Germany) to B Weide. Parts of this study were funded by the EU Seventh Framework Program ‘PRIAT’ (Profiling Responders In Antibody Therapies) grant agreement no 305309 to C Garbe. Parts of this study were funded by Deutsche Forschungsgemeinschaft DFG PA 361-22/1 to G. Pawelec., European Project: 305309,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,PRIAT(2012), Bernardo, Elizabeth, Profiling Responders In Antibody Therapies - PRIAT - - EC:FP7:HEALTH2012-11-01 - 2014-10-31 - 305309 - VALID, Immunité et cancer ( U932 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut Curie-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Memorial Sloan Kettering Cancer Center [New York, NY, USA], Weill Cornell Medical College [New York, NY, USA], German Cancer Consortium - DKTK [Heidelberg, Germany], Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Nottingham Trent University [U.K.], European Project : 305309,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,PRIAT ( 2012 ), Universität Duisburg-Essen = University of Duisburg-Essen [Essen]-University Hospital [Essen, Germany]-West German Cancer Center [Essen, Germany]

المصدر: European Journal of Cancer
European Journal of Cancer, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. 〈10.1016/j.ejca.2016.12.011〉
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩

مصطلحات موضوعية: CD4-Positive T-Lymphocytes, Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Programmed Cell Death 1 Receptor, Medizin, Kaplan-Meier Estimate, CD8-Positive T-Lymphocytes, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Biomarker, Effector memory cells, Ipilimumab, Melanoma, Prognosis, medicine.diagnostic_test, Effector, Antibodies, Monoclonal, Middle Aged, Flow Cytometry, Peripheral, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, medicine.drug, Adult, medicine.medical_specialty, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Peripheral blood mononuclear cell, Article, Flow cytometry, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Antigens, Neoplasm, Internal medicine, Biomarkers, Tumor, medicine, Humans, Aged, business.industry, medicine.disease, 030104 developmental biology, Immunology, business, Immunologic Memory, CD8

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a6982f18635313131b596d20ee2f8dTest
https://doi.org/10.1016/j.ejca.2016.12.011Test

المؤلفون: Christian U. Blank, Scot Ebbinghaus, Reinhard Dummer, Carmen Loquai, Steven J. O'Day, Antoni Ribas, Adil Daud, Jacob Schachter, Caroline Robert, Janice M. Mehnert, Dirk Schadendorf, S. Peter Kang, Wei Zhou, Igor Puzanov, Darcy A. Hille, April K.S. Salama, Omid Hamid, Lee D. Cranmer, Alfons J.M. van den Eertwegh, Axel Hauschild

المساهمون: University of Zurich, Schadendorf, Dirk, Medical oncology, CCA - Clinical Therapy Development

المصدر: Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, J M, Hille, D, Ebbinghaus, S, Kang, S P, Zhou, W & Ribas, A 2016, ' Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma ', European Journal of Cancer, vol. 67, pp. 46-54 . https://doi.org/10.1016/j.ejca.2016.07.018Test
European Journal of Cancer, 67, 46-54. Pergamon

مصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, Health Status, Health-related quality of life, medicine.medical_treatment, Medizin, Pembrolizumab, Carboplatin, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, 030212 general & internal medicine, Melanoma, Aged, 80 and over, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Dacarbazine, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, medicine.drug, Adult, KEYNOTE-002, medicine.medical_specialty, Adolescent, Paclitaxel, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, Temozolomide, medicine, Humans, Chemotherapy, In patient, Patient Reported Outcome Measures, Aged, Patient-reported outcomes, business.industry, Cancer, EORTC QLQ-C30, medicine.disease, Surgery, Quality of Life, business, Ipilimumab-refractory melanoma

وصف الملف: 663_Schadendorf D. et al._Health-related quality of life in the randomised KEYNOTE-002_EJC 2016.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0340a48931fc5ff52f9246c04eeed519Test
https://doi.org/10.1016/j.ejca.2016.07.018Test

المؤلفون: H. van Tinteren, J.B.A.G. Haanen, Christian U. Blank, A. Scholtens, J.V. van Thienen, M.H. Geukes Foppen

المصدر: European Journal of Cancer. 51:642-652

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, Cancer Research, medicine.medical_specialty, Indoles, Skin Neoplasms, Time Factors, Kaplan-Meier Estimate, Disease-Free Survival, Drug Administration Schedule, Risk Factors, Internal medicine, Humans, Medicine, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Netherlands, Proportional Hazards Models, Retrospective Studies, Response rate (survey), Sulfonamides, business.industry, Standard treatment, Hazard ratio, Retrospective cohort study, Dabrafenib, Middle Aged, medicine.disease, Treatment Outcome, Multivariate Analysis, Mutation, Cutaneous melanoma, Immunology, Disease Progression, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09fe2cb4cae628f7cac178c9d319b2d9Test
https://doi.org/10.1016/j.ejca.2015.01.009Test